Ivonescimab  (Synonyms: AK112)

Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL)^{[1][2][3][4][5]}.

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

VEGFA & PDCD1

Ivonescimab binds to PD-1 and VEGFA with EC₅₀s of 0.06 and 0.036 nM^[2].
Ivonescimab can form soluble complexes with VEGF (by SEC-HPLC assay)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

7422  [NCBI] & 5133  [NCBI]

P15692 & Q15116

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

201.1 kDa

2428381-53-5

Liquid

Colorless to light yellow

[Ivonescimab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa-[scFv-heavy-kappa]2

• 
  Loaded Ivonescimab on AHC2 biosensor, can bind PD-1 Protein, Human (143a.a, HEK293, His, HY-P7396) with an affinity constant of 2.252E-08 M as determined in BLI assay.
• 
  Loaded Ivonescimab on AHC2 biosensor, can bind FITC-Labeled VEGF165 Protein, Human (HEK293, C-His, HY-P701279) with an affinity constant of <1.000E-11 M as determined in BLI assay.

• [1]. Coward J, et al. Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study. Journal for Immuno Therapy of Cancer 2021;9:

  [2]. Zhong T, et al. AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies. Journal for Immuno Therapy of Cancer. 2022;10:

  [3]. Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. Journal for Immuno Therapy of Cancer. 2022;10:e005517.

  [4]. Dhillon S. Ivonescimab: First Approval. Drugs. 2024 Sep;84(9):1135-1142.  [Content Brief]

  [5]. Fang W, et al. Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial. JAMA. 2024 Aug 20;332(7):561-570.  [Content Brief]